Cancer Survival with TNF Inhibitors (3.28.2025)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

  1. Korea National Health Insurance Database review shows that risk of mortality in Behcets patients is 28% higher than gen. population; highest in 1st 12 mos (OR 2.66). Major causes were CA, CVD, GI (viscus rupture), respiratory, & infections. Higher in younger pts. https://buff.ly/RpF5xrP
  2. MD Anderson Cancer Center study of 1991 RA pts w/ prostate, lung or colon cancer showed TNFi use in 1st 3yrs did NOT affect survival. Use of TNFi vs csDMARDs - nonsign lowering in CRCA (HR 0·72;0·43–1·21), Lung CA (0·70;0·49–1·00), Prostate CA (0·80;0·44–1·44) https://t.co/6NsMYocdEl
  3. Machine learning model can predict RA progression from seroneg (SN) undiff. arthritis. KURAMA cohort -210 SN pts -- 57 (27%) progressed to RA. FNN model best w/ AUC 0.924 & sensitivity 81%. Validated in ANSWER cohort (140 pts; 32% became RA) AUC 0.77 sensitivity 78%. MMP-3 had https://t.co/2kiAU8r3B8
  4. In 2021, the worldwide market for rheumatoid arthritis was valued at USD 22.77 billion and is projected to grow to USD 33.30 billion by 2030. https://t.co/HoUdQZfU8Q
  5. A study in mice shows that JAK inhibition In mice model of status epilepticus (SE) didnt prevent initial SE but when did effect chronic phase of Sz weeks after SE induction of SE, suppressing seizures, and epilepsy-associated histopathological alterations. Sz suppression lasted https://t.co/GMIPCtoc7x
  6. ACPA specificity and recognition motifs examined in 6,907 patients with RA from 5 Scandinavian cohorts. ACPA targeting non-glycine citrulline motifs assoc. more strongly w/ HLA-SE; ACPA to glycine citrulline motifs assoc. w/ smoking and IgA ACPA A&R https://t.co/PmKv3dZLc4
  7. Dr. Swamy Venuturupalli, a Community Practice Innovation Award recipient, is transforming telehealth in rheumatology! His project introduces an innovative app that empowers patients to examine their own joints—making high-quality telehealth a seamless part of care. https://t.co/R5M4jtVz5m
  8. Post hoc analysis of 5 ph III Belimumab RCTs (BLISS, etc, N=3086) on skin outcomes BILAG & SLEDAI-2K), BEL was superior to PBO (mcBILAG OR: 1.29; mcSLEDAI-2K OR: 1.37). Also if SLEDAI ≥10 & dsDNA+ pts. BEL prevented skin flares (HR 0.70) https://t.co/p1MVVf97Go
  9. 55 myositis (IIM) pts studied Nailfold Capillaries, MSAbs, cytokines & IFN genes. MDA5(+) pts signif more dilated (DIL), giant & abnl morphology caps, w/ microhemorrhages (MH) vs ARS (+) pts. MH & DIL assoc w/ MX1, IFI27, IP-10, RANTES, GROα. Giant caps assoc w/ IFI27, SDF-1α, https://t.co/3WQL8Sw0rq
  10. J&J announced the FDA jas granted the investigational drug, nipocalimab (FcRn recpt Ab), with Fast Track designation for its study in adult patients with moderate-to-severe Sjögren’s disease https://t.co/5rEYHkGVp2 https://t.co/ny2dv6Jtr5
  11. Worse Outcomes in HLA-B27+ JIA 
  12. Targeting Obesity in Rheumatic Disease Patients
  13. Repetitive Transcranial Magnetic Stimulation in Fibromyalgia

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject
×